Clinical trials: Higher Risk Myelodysplastic Syndrome
Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML)
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are…
- Conditions
- Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML)
- Trial name
- NCT00566696
- Testing
- CliniMACS, Stem cell transplantation, Fludarabine
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic…
- Trial name
- NCT01031498
- Testing
- Ondansetron, Palonosetron
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory…
- Trial name
- NCT05732103
- Testing
- CTX-712
- Where
- 8 sites in United States
- Volunteers
- 225 people
- Sponsor
- Chordia Therapeutics, Inc.
Higher-risk Myelodysplastic Syndromes
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.
- Trial name
- NCT06471946
- Testing
- Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Navy General Hospital, Beijing
Myelodysplastic Syndrome, Acute Myeloblastic Leukemia
SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
Association group of therapeutic specialities authorized in a remission induction treatment(FLAG-IDA: fludarabine, cytarabine, G-CSF (lenograstim) and idarubicin) and an intensive postremission treatment with authorized…
- Trial name
- FLAG-IDA (NCT00487448)
- Testing
- Fludarabine, Cytarabine, G-CSF
- Where
- 15 sites in Spain
- Volunteers
- 200 people
- Sponsor
- PETHEMA Foundation
Leukemia
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
The goal of this clinical research study is to learn if lirilumab and Opdivo (nivolumab), alone or in combination with Vidaza (azacitidine), can help to control MDS. The safety of these drug combinations will also be studied.
- Trial name
- NCT02599649
- Testing
- Lirilumab, Nivolumab, Azacitidine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes
A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
This is a Phase 2, two-stage study of the safety and efficacy of pracinostat in combination with azacitidine in patients with IPSS-R high and very high risk myelodysplastic syndrome (MDS) who are previously untreated with…
- Trial name
- NCT03151304
- Testing
- Pracinostat, Azacitidine
- Where
- 25 sites in United States
- Volunteers
- 64 people
- Sponsor
- Helsinn Healthcare SA
Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
- Trial name
- NCT05961839
- Testing
- SGR-2921
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- Schrödinger, Inc.
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
This phase I/II trial studies the side effects and best dose of decitabine followed by mitoxantrone hydrochloride, etoposide, and cytarabine and to see how well they work in treating patients with acute myeloid leukemia or…
- Trial name
- NCT01729845
- Testing
- Cytarabine, Decitabine, Etoposide
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
This phase I/II trial studies the side effects of laboratory-treated T cells and to see how well they work in treating patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT01640301
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6)
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase I trial is studying the side effects and best dose of tipifarnib in treating patients with relapsed or refractory…
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00101296
- Testing
- tipifarnib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes
A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
The study is designed to determine the efficacy and safety of roxadustat for the treatment of anemia due to very low, low, or intermediate risk MDS in participants with high transfusion burden (HTB).
- Trial name
- NCT07722988
- Testing
- Roxadustat
- Volunteers
- 201 people
- Sponsor
- Kyntra Bio
Acute Myeloid Leukemia, Myelodysplastic Syndromes
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
This is a first-in-human dose escalation/dose expansion study to evaluate the safety and identify the best dose of modified immune cells, PRGN-3006 (autologous chimeric antigen receptor (CAR) T cells), in adult patients with…
- Trial name
- NCT03927261
- Testing
- PRGN-3006 T Cells
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Precigen, Inc
MDS, AML
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
Clofarabine is known to have a stronger anti-tumor effect than Fludarabine and has shown its efficacy in treating aggressive acute leukemias.
- Conditions
- MDS, AML, ALL, BAL
- Trial name
- Cloric (NCT00863148)
- Testing
- Clofarabine in combination with IV busulfan and ATG
- Where
- 6 sites in France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
High Risk MDS or AML Patients
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
The purpose of this trial is to examine the hematologic response rate of Exjade® in patients with AML and high risk MDS and chronic iron overload from blood transfusions.
- Trial name
- NCT02233504
- Testing
- Exjade® (deferasirox, ICL670)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hematologic Malignancy, Bone Marrow Transplant Rejection
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor…
- Conditions
- Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT06398457
- Testing
- Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Myelodysplastic Syndromes
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Monoclonal antibodies such as gemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00022321
- Testing
- gemtuzumab ozogamicin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk…
- Conditions
- Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
- Trial name
- NCT03787498
- Testing
- PLX2853
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Opna Bio LLC
Myelodysplastic Syndromes
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason…
- Trial name
- NCT02281084
- Testing
- Oral Azacitidine, Durvalumab
- Where
- 89 sites in United States, Australia and 8 more
- Volunteers
- 65 people
- Sponsor
- Celgene
Acute Leukaemia, Chronic Disease
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
This is a phase II trial of reduced intensity conditioning with Bu/Flu/ATG in pediatric patients with hematologic malignancies at high risk for transplant related mortality with standard transplantation.
- Conditions
- Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia
- Trial name
- NCT00795132
- Testing
- Busulfan, Anti-Thymocyte Globulin, Fludarabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Utah